Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha

Arthritis Rheum. 1996 Feb;39(2):197-203. doi: 10.1002/art.1780390205.

Abstract

Objective: To examine whether nuclear factor kappaB (NF-kappaB) is activated in cultured synovial cells in response to tumor necrosis factor alpha (TNFalpha) and to investigate the correlation between NF-kappaB activation and synovial cell proliferation.

Methods: Activation of NF-kappaB was detected by electrophoretic mobility shift assay. The transcription of several NF-kappaB-dependent genes was evaluated by reverse transcriptase polymerase chain reaction and transient expression assay using human immunodeficiency virus-long terminal repeat chloramphenicol acetyltransferase. Proliferative activity was determined by measurement of 3H-thymidine incorporation.

Results: Stimulation of synovial cells with TNFalpha activated NF-kappaB and subsequent transcription of several genes. Treatment of synovial cells with N-acetyl-L-cysteine (NAC), an antioxidant agent, inhibited TNFalpha-induced NF-kappaB activation and transcription. Moreover, NAC also inhibited synovial cell proliferation induced by TNFalpha.

Conclusion: Our results suggest that NF-kappaB plays a pivotal role in synovial cell activation by TNFalpha. Thus, suppression of NF-kappaB could be a potential therapeutic modality for synovitis such as that of rheumatoid arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology
  • Base Sequence
  • Cell Division / drug effects
  • Cells, Cultured
  • Humans
  • Molecular Sequence Data
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / physiology*
  • Synovial Membrane / cytology
  • Synovial Membrane / drug effects
  • Synovial Membrane / physiology*
  • Transcription, Genetic / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • NF-kappa B
  • Tumor Necrosis Factor-alpha
  • Acetylcysteine